Kinga Burda
Overview
Explore the profile of Kinga Burda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
60
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szkutnik-Fiedler D, Kus K, Balcerkiewicz M, Grzeskowiak E, Nowakowska E, Burda K, et al.
Pharmacol Rep
. 2013 Feb;
64(6):1350-8.
PMID: 23406745
Background: The aim of this study was to evaluate antidepressant-like effect (Porsolt test), locomotor activity and motor coordination of joint administration of tramadol (TRM) and venlafaxine (VEN) in rats. Methods:...
2.
Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P, Zin J
Pharmacol Rep
. 2011 Oct;
63(4):898-907.
PMID: 22001977
Recent research has suggested that cognitive disorders are a persistent trait of mental illnesses such as schizophrenia. Cognitive deficits in the course of schizophrenia may be due to the disease...
3.
Nowakowska E, Kus K, Polanski A, Burda K, Nowakowska A, Sadowski C
Pharmacol Rep
. 2011 May;
63(2):372-80.
PMID: 21602592
As shown in clinical studies, combinations of first generation normothymics (carbamazepine - CBZ) with atypical neuroleptics (olanzapine - OLA) lead to improvements in approximately half of patients treated for relapses...
4.
Burda K, Czubak A, Nowakowska E, Kus K, Metelska J, Nowakowska A
Arzneimittelforschung
. 2010 Dec;
60(9):527-43.
PMID: 21117496
Cognitive disorders in the course of mental illnesses are one of the most important and most difficult therapeutic problems related to those illnesses and they regard attention, memory, learning and...
5.
Kus K, Burda K, Nowakowska E, Czubak A, Metelska J, Lancucki M, et al.
Arzneimittelforschung
. 2010 Sep;
60(8):471-8.
PMID: 20863002
Deficits of cognitive functions are perceived as an important pathogenic factor of many neurological and psychiatric diseases. Such symptoms can be a result of a disease process or appear due...
6.
Nowakowska E, Czubak A, Kus K, Metelska J, Burda K, Nowakowska A
Arzneimittelforschung
. 2010 Jul;
60(6):307-14.
PMID: 20648919
Epileptic patients are at risk of experiencing cognitive deficits as a result of pharmacotherapy as well as etiology of epilepsy. Antiepileptic drugs increase inhibitory neurotransmission and reduce the responsiveness of...
7.
Czubak A, Nowakowska E, Burda K, Kus K, Metelska J
Arzneimittelforschung
. 2010 Feb;
60(1):1-11.
PMID: 20184221
Many patients undergoing long-term treatment of epilepsy complain of memory disorders, which entail worse quality of life. The risk factors generating memory disorders include: morphological brain damage, the duration and...
8.
Czubak A, Nowakowska E, Kus K, Burda K, Metelska J, Baer-Dubowska W, et al.
Pharmacol Rep
. 2010 Jan;
61(6):1017-23.
PMID: 20081236
Brain-derived neurotrophic factor (BDNF) is a key neurotrophic factor in the brain. It plays an important role in the etiopathogenesis and pharmacotherapy of mental disorders, such as depression or schizophrenia....